Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Starpharma Holdings's annualized net income for the quarter that ended in Dec. 2025 was A$2.73 Mil. Starpharma Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$20.24 Mil. Therefore, Starpharma Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 13.51%.
The historical rank and industry rank for Starpharma Holdings's Return-on-Tangible-Equity or its related term are showing as below:
ASX:SPL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -64.31 Med: -33.7 Max: 16.03
Current: -15.23
During the past 13 years, Starpharma Holdings's highest Return-on-Tangible-Equity was 16.03%. The lowest was -64.31%. And the median was -33.70%.
ASX:SPL's Return-on-Tangible-Equity is ranked better than 66.17% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs ASX:SPL: -15.23
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Starpharma Holdings Return-on-Tangible-Equity Related Terms
Starpharma Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SPL vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Starpharma Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.51% mean?
Starpharma Holdings (ASX:SPL) has a Return-on-Tangible-Equity of 13.51% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #406 out of 1200 companies in the Biotechnology industry, placing it in the top 33.8%.
Is Starpharma Holdings' Return-on-Tangible-Equity too high?
Starpharma Holdings' current Return-on-Tangible-Equity is 13.51%. Based on the distribution chart, Starpharma Holdings ranks #406 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #406 out of 1200 companies for Return-on-Tangible-Equity. This puts Starpharma Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Return-on-Tangible-Equity is 13.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.71 — trading 65.1% above its estimated fair value. The current Return-on-Tangible-Equity is 13.51%. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Return-on-Tangible-Equity is 13.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.71 is trading 65.1% above its estimated GF Value™ of A$0.43.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
Return-on-Tangible-Equity: 13.51%
GF Value™: A$0.43 vs. price of A$0.71 (65.1% above fair value)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score
Get the complete analysis for ASX:SPL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
